In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
As of close of business last night, GoodRx Holdings Inc’s stock clocked out at $3.52, down -3.83% from its previous closing price of $3.66. In other words, the price has decreased by -$3.83 from its previous closing price. On the day, 3.2 million shares were traded. GDRX stock price reached its highest trading level at $3.6987 during the session, while it also had its lowest trading level at $3.4812.
Ratios:
To gain a deeper understanding of GDRX’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.35 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 6.45. For the most recent quarter (mrq), Quick Ratio is recorded 4.21 and its Current Ratio is at 4.21. In the meantime, Its Debt-to-Equity ratio is 0.85 whereas as Long-Term Debt/Eq ratio is at 0.84.
On December 04, 2024, Mizuho started tracking the stock assigning a Neutral rating and target price of $5.
Raymond James Upgraded its Outperform to Strong Buy on August 09, 2024, while the target price for the stock was maintained at $10.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Oct 15 ’25 when Spectrum Equity VII, L.P. sold 23,771 shares for $4.00 per share. The transaction valued at 95,103 led to the insider holds 0 shares of the business.
Spectrum VII Co-Investment Fun bought 8,569 shares of GDRX for $34,447 on Oct 15 ’25. On Oct 15 ’25, another insider, Spectrum VII Investment Manage, who serves as the Affiliate of the company, bought 15,202 shares for $4.02 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GDRX now has a Market Capitalization of 1223024000 and an Enterprise Value of 1489244032. As of this moment, GoodRx’s Price-to-Earnings (P/E) ratio for their current fiscal year is 37.93, and their Forward P/E ratio for the next fiscal year is 7.72. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 2.41. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.53 while its Price-to-Book (P/B) ratio in mrq is 1.93. Its current Enterprise Value per Revenue stands at 1.862 whereas that against EBITDA is 11.063.
Stock Price History:
The Beta on a monthly basis for GDRX is 1.20, which has changed by -0.42483658 over the last 52 weeks, in comparison to a change of 0.20772064 over the same period for the S&P500. Over the past 52 weeks, GDRX has reached a high of $6.52, while it has fallen to a 52-week low of $3.31. The 50-Day Moving Average of the stock is -15.79%, while the 200-Day Moving Average is calculated to be -20.72%.
Shares Statistics:
It appears that GDRX traded 4.64M shares on average per day over the past three months and 2817000 shares per day over the past ten days. A total of 99.90M shares are outstanding, with a floating share count of 81.41M. Insiders hold about 76.57% of the company’s shares, while institutions hold 15.96% stake in the company. Shares short for GDRX as of 1760486400 were 8252836 with a Short Ratio of 1.78, compared to 1757894400 on 5590466. Therefore, it implies a Short% of Shares Outstanding of 8252836 and a Short% of Float of 9.45.
Earnings Estimates
The dynamic stock of GoodRx Holdings Inc (GDRX) is currently being evaluated by a team of 12.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $0.1, with high estimates of $0.11 and low estimates of $0.08.
Analysts are recommending an EPS of between $0.4 and $0.34 for the fiscal current year, implying an average EPS of $0.37. EPS for the following year is $0.46, with 12.0 analysts recommending between $0.51 and $0.39.
Revenue Estimates
In. The current quarter, 13 analysts expect revenue to total $194.51M. It ranges from a high estimate of $197.48M to a low estimate of $192.54M. As of. The current estimate, GoodRx Holdings Inc’s year-ago sales were $195.25MFor the next quarter, 13 analysts are estimating revenue of $197.6M. There is a high estimate of $202.12M for the next quarter, whereas the lowest estimate is $194.1M.
A total of 15 analysts have provided revenue estimates for GDRX’s current fiscal year. The highest revenue estimate was $804.6M, while the lowest revenue estimate was $794.01M, resulting in an average revenue estimate of $797.96M. In the same quarter a year ago, actual revenue was $792.32MBased on 15 analysts’ estimates, the company’s revenue will be $840.24M in the next fiscal year. The high estimate is $871.41M and the low estimate is $816.1M.
